Physician profile
Rose Eapen
NPI 1861612772
$12,170.32
in general payments reported to CMS, 2019-2025
14 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what 88% of Pediatric Otolaryngology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,268 · 2020: $2,038 · 2021: $1,432 · 2022: $650 · 2023: $2,469 · 2024: $2,919 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,375 · Travel and Lodging: $2,102 · Food and Beverage: $1,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,375.00 |
| Travel and Lodging | $2,102.02 |
| Food and Beverage | $1,305.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karl Storz Endoscopy-America | $8,254.43 | 2019-2024 | N.A. |
| Smith+Nephew, INC. | $2,305.50 | 2019-2025 | Tula, Trigen, Coblation |
| Integra Lifesciences Corporation | $788.96 | 2024 | Inspira Air, Acclarent Aera |
| Stryker Corporation | $217.35 | 2024-2025 | Xpress Loprofile, Latera, Scopis Ent |
| Merz Pharmaceuticals, LLC | $149.91 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $149.42 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $62.35 | 2025 | Nucala |
| Genzyme Corporation | $60.34 | 2021-2025 | |
| Medtronic, INC. | $42.77 | 2025 | Pteye Parathyroid Detection System |
| Optinose US, INC. | $33.50 | 2025 | |
| Inspire Medical Systems, INC. | $32.50 | 2025 | Inspire |
| Ars Pharmaceuticals Operations, INC. | $28.85 | 2025 | Neffy |
| Baxter Healthcare | $27.89 | 2025 | Perclot |
| Hikma Pharmaceuticals USA | $16.55 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rose Eapen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.